J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma

Johnson & Johnson and Legend Biotech reported that their CAR-T therapy Carvykti maintained long-term survival benefits in multiple myeloma patients with half of the treated cohort alive and disease progression-free after five years in the Phase 2 CARTITUDE-2 study. Carvykti, targeting BCMA, is FDA approved and generating nearly $1.9 billion in annual sales, while Gilead's anito-cel is poised as a competitor with FDA review pending.

This Wire brief sits within Fusion42's coverage of Biotech.